Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This article reviews clinical trial data that assesses the safety, efficacy, and clinical application of spesolimab, an interleukin-36 (IL-36) blocker, for the treatment of generalized pustular psoriasis (GPP).
Data Sources: A review of the literature was conducted using the search terms: "spesolimab," "BI 655130," and "spevigo" in MEDLINE (PubMed) and Clinicaltrials.gov from January 1, 1950 to October 31, 2023.
Study Selection And Data Extraction: Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of spesolimab were included.
Data Synthesis: In one phase 2 clinical trial evaluating single dose IV spesolimab for GPP flares at day 8, 54% of patients receiving spesolimab had a GPP physician global assessment (GPPGA) pustulation subscore of 0, and 43% had a GPPGA total score of 0 compared with 6% and 11% for the placebo group, respectively. Another phase 2 clinical trial assessing subcutaneous spesolimab found 23% of patients in low-dose, 29% in medium-dose, and 10% of high-dose spesolimab had flares by week 48 compared with 52% of the placebo group. Hazard ratios for time to GPP flare compared with placebo were 0.16 ( = 0.0005), 0.35 ( = 0.0057), and 0.47 ( = 0.027) for the spesolimab groups, respectively. Infection rates were similar across treatment and placebo groups, and severe adverse events such as drug reactions with eosinophilia and systemic symptom (DRESS), cholelithiasis, and breast cancer occurred with spesolimab.
Relevance To Patient Care And Clinical Practice In Comparison To Existing Drugs: Spesolimab is a first-in-class IL-36 monoclonal antibody receptor antagonist approved for the treatment of acute GPP flares. It is a safe and effective therapeutic agent in preventing future GPP flares, with no current comparator trials with other GPP agents.
Conclusion: Spesolimab is a safe and effective treatment for acute GPP flares in adults. Future clinical trials can establish safety and efficacy compared with other agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10600280241252688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study.
Ann Dermatol Venereol
September 2025
Department of Dermatology, René Dubos Hospital, Pontoise, France.
Background: Generalized pustular psoriasis (GPP) is a rare, severe, chronic neutrophilic skin disease involving the interleukin-36 (IL-36) pathway.
Objective: The main objective of the SCRIPTOR international non-interventional study was to describe sociodemographic and clinical characteristics of GPP. This paper focuses on data collected from participating French centers.
Real-world treatment patterns in patients with generalized pustular psoriasis (GPP).
J Am Acad Dermatol
August 2025
Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA. Electronic address:
Background: Generalized pustular psoriasis (GPP) is a chronic and life-threatening inflammatory skin disease, distinct from plaque psoriasis (PsO). There is a lack of GPP treatment guidelines.
Objective: To characterize treatment patterns among patients with GPP in the US during two 365-day periods (post-diagnosis and pre-diagnosis) between 2015 and 2020.
Health-related quality of life of adults with generalized pustular psoriasis in Malaysia: a cross-sectional study.
Orphanet J Rare Dis
August 2025
Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Background: Generalized Pustular Psoriasis (GPP) is a rare but severe form of psoriasis, characterized by flares involving the sudden spread of erythema with sterile pustules, crusting, and scaling.
Objective: The study aimed to assess both generic and dermatology-specific health-related quality of life (HRQoL) in patients with GPP across flare and non-flare stages in Malaysia.
Methods: The study was a multicenter cross-sectional study conducted among patients diagnosed with GPP attending the General Hospitals under the Ministry of Health, Malaysia, between May 15, 2024, and November 30, 2024.
A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys.
Dermatol Ther (Heidelb)
August 2025
Department of Dermatology, Xijing Hospital-Fourth Military Medical University, Xi'an, China.
Introduction: Generalized pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease that significantly impacts patients' quality of life (QoL). A multinational panel of patients with GPP participated in surveys and interviews, with the aim to assess the impact of chronic symptoms and GPP flares on QoL and well-being, and to better understand the resources and support that patients need.
Methods: Patients (aged 18-65 years) with a confirmed diagnosis of GPP (> 1 month), who had experienced ≥ 1 flare in the past year and were receiving active treatment for GPP were recruited through databases and healthcare professionals (HCPs).
Achieving Therapeutic Success with Spesolimab: Two Cases of Drug-Induced Generalized Pustular Psoriasis Initially Mimicking Acute Generalized Exanthematous Pustulosis.
J Inflamm Res
July 2025
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Background: Patients with newly diagnosed generalized pustular psoriasis (GPP) lacking a history of psoriasis but with recent medication exposure may present with clinical features overlapping with acute generalized exanthematous pustulosis (AGEP). Accurate differentiation is critical for treatment and prognosis.
Case Summary: We report two cases of drug-induced GPP initially with AGEP-like manifestations.